R+D Biomarker Discovery

Our aim is to elucidate the role genes play in cancer development and use this knowledge to improve patient care through development of novel molecular diagnostic tools. We aim to improve treatment, and therefore survival, through identification of novel theranostic biomarkers that can be rapidly incorporated into clinical practice. We focus on validation of new gene signatures predictive of response to adjuvant and neoadjuvant treatment and are currently investigating new genetic markers for breast and lung cancer.

The Pangaea team is composed of both prestigious clinical and research professionals and combines expertise in preclinical cancer research with extensive experience in R+D Diagnostics and Drug Development.

In-house and through partnerships we perform comprehensive pathology, molecular biology, in vitro and in vivo techniques:

  • Mutation analysis in tumor tissue and blood

  • Gene amplification and translocation testing

  • Immunohistochemistry (IHC)

  • Gene expression

  • MTT proliferation assays

  • Western blotting

  • Colony formation, migration and invasion assays

  • Molecular profiling of cell lines and tissue samples

  • Gene silencing

We have the capacity to work with formalin-fixed paraffin-embedded tumor tissue, fresh frozen samples, serum, plasma, platelets and cytologies.
For further details of our R+D biomarker discovery program: Contact us


We use first and third party cookies to track your browsing habits on our website in order to provide you with better quality and security, and improve the services offered through this website. If users do not explicitly confirm that they consent to the installation of cookies but continue to browse our website, we will assume that they have agreed and we will inform them accordingly about the possibility of blocking or deleting any previously installed cookies by adjusting their browser settings. You can find out more about cookies in our "Cookie Policy".